Abstract |
Between July 1983 and May 1987 143 untreated patients with Hodgkin's lymphoma in stages I-IIIA with risk factors qualified for the HD1 protocol, and 230 patients in stages IIIB/IV qualified for HD3. Patients in HD1 received a combined chemo- radiotherapy (2 x COPP + ABVD + 20 Gy EF vs. 40 Gy EF). Patients in HD3 received induction chemotherapy (3 x COPP + ABVD) and were randomized into consolidation by radiotherapy (20 Gy IF) vs. chemotherapy (1 x COPP + ABVD). In HD1, 73 of 89 evaluable patients (82%) achieved a complete remission. The survival of patients in stages I-IIIA with risk factors treated according to HD1 is as good as the survival of patients in stages I and II without risk factors. In HD3, 86 of 137 patients (63%) achieved complete remission after induction chemotherapy with 3 x COPP + ABVD. This is significantly better than the 31% complete remission rate observed in a pilot study with COPP alone (p less than 0.01). Including salvage therapy ( radiotherapy in case of persisting nodal disease; chemotherapy with 4 x CEVD in case of persisting disseminated disease), a total of 76% complete remissions in stages IIIB/IVAB were achieved. An ESR greater than 80 mm/h was the most significant single risk factor in stages IIIB/IV for induction of CR and freedom from progression.
|
Authors | M Pfreundschuh, M Löffler, U Rühl, E Hiller, H Gerhartz, W Wilmanns, H Kirchner, W Schoppe, S Petsch, H Bartels |
Journal | Onkologie
(Onkologie)
Vol. 11
Issue 1
Pg. 48-52
(Feb 1988)
ISSN: 0378-584X [Print] Switzerland |
Vernacular Title | Therapie der Hodgkin-Lymphome. Ergebnisse der Deutschen Hodgkin-Studiengruppe. |
PMID | 2452393
(Publication Type: Clinical Trial, English Abstract, Journal Article, Randomized Controlled Trial, Research Support, Non-U.S. Gov't)
|
Chemical References |
- Bleomycin
- Procarbazine
- Vincristine
- Vinblastine
- Dacarbazine
- Doxorubicin
- Cyclophosphamide
- Prednisone
|
Topics |
- Adolescent
- Adult
- Antineoplastic Combined Chemotherapy Protocols
(therapeutic use)
- Bleomycin
(administration & dosage)
- Clinical Trials as Topic
- Combined Modality Therapy
- Cyclophosphamide
(administration & dosage)
- Dacarbazine
(administration & dosage)
- Doxorubicin
(administration & dosage)
- Female
- Germany, West
- Hodgkin Disease
(drug therapy, pathology, radiotherapy)
- Humans
- Male
- Middle Aged
- Neoplasm Staging
- Prednisone
(administration & dosage)
- Procarbazine
(administration & dosage)
- Random Allocation
- Vinblastine
- Vincristine
(administration & dosage)
|